tildrakizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5281 1326244-10-3

Description:

MoleculeDescription

Molfile

Synonyms:

  • tildrakizumab
  • ilumya
  • tildrakizumab-asmn
  • MK-3222
  • SCH-900222
  • SUNPG 1622
  • SUNPG 1623
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
1.11 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 29, 2020 PMDA Sun Pharma Japan Ltd.
March 20, 2018 FDA SUN PHARMA GLOBAL
Sept. 17, 2018 EMA ALMIRALL SA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 165.65 40.26 64 533 291623 90336227
Death 84.07 40.26 46 551 456505 90171345
Self-medication 57.89 40.26 11 586 3209 90624641
Drug ineffective 54.79 40.26 55 542 1384243 89243607
Therapy cessation 43.35 40.26 14 583 36347 90591503

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 148.10 46.20 63 600 154302 42466370
Death 80.06 46.20 62 601 471123 42149549
Drug ineffective 60.48 46.20 60 603 630137 41990535

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product dose omission issue 77.83 39.36 39 686 321743 110266831
Death 63.55 39.36 45 680 698824 109889750
Psoriasis 39.72 39.36 19 706 139974 110448600

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC17 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000192798 Interleukin-23 Antagonists
FDA EPC N0000192799 Interleukin-23 Antagonist
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50748 antipsoriatic

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabbrodalumabcanakinumabdaclizumabguselkumabixekizumabmirikizumabrilonaceptrisankizumabsarilumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Plaque psoriasis indication 200965009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-23 Cytokine ANTIBODY BINDING Kd 9.50 IUPHAR DRUG LABEL

External reference:

IDSource
DEW6X41BEK UNII
4037782 VANDF
4037783 VANDF
C4043954 UMLSCUI
CHEBI:753629 CHEBI
CHEMBL2108681 ChEMBL_ID
DB14004 DRUGBANK_ID
D10400 KEGG_DRUG
9672 INN_ID
C000598434 MESH_SUPPLEMENTAL_RECORD_UI
8093 IUPHAR_LIGAND_ID
771591006 SNOMEDCT_US
771665003 SNOMEDCT_US
277523 MMSL
34167 MMSL
d08783 MMSL
017483 NDDF
2053436 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ILUMYA HUMAN PRESCRIPTION DRUG LABEL 1 47335-177 INJECTION, SOLUTION 100 mg SUBCUTANEOUS BLA 25 sections